Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Dr. Mark Rigby (Indiana University) are published today in The Lancet Diabetes & Endocrinology.
It is with great sadness that we report the passing of Lloyd Mayer, MD.
Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) with the Immune Tolerance Network (ITN), were published in an article today in The Lancet Diabetes & Endocrinology. The study enrolled 58 new-onset type 1 diabetic subjects ages 12-35.
In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org).
In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare
The Immune Tolerance Network’s (ITN’s) IMPACT Study, “Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children,” opened for enrollment today. This will be the first major study to examine whether oral immunotherapy can lead to durable, lasting tolerance to peanut among young peanut-allergic children. This study will be led by ITN investigator Wesley Burks, MD, Chair of the Department of Pediatrics at UNC Chapel Hill.
Primary results from the Immune Tolerance Network’s AbATE study (Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes) were published online today in Diabetes. The Phase II AbATE study, led by Kevan Herold, MD (Yale University), tested two doses of anti-CD3 given one year apart in new onset type 1 diabetics compared to control.
In a letter published recently in the Journal of Allergy and Clinical Immunology, Immune Tolerance Network (ITN) investigators describe the experience of the ITN’s GPAC study (Immunoprophylaxis of Allergic Disease) that aimed to test whether early intervention with a form of oral immunotherapy in at-risk young children could prevent the development of asthma.
Data from three ITN type 1 diabetes trials will be featured during the “Clinical Trials of T Cell Therapeutics for Reversing Type 1 Diabetes” session at the Annual American Diabetes Association (ADA) Scientific Sessions in Chicago, IL. This session will take place on June 22 from 8:00am-10:00am CT.
In a manuscript published this week in Arthritis & Rheumatism, Immune Tolerance Network (ITN) investigators sought to better understand the distinction between patients who did and did not achieve the primary endpoint in the RAVE Study (Rituximab for the Treatment of ANCA-Associated Vasculitis and Microscopic Polyangiitis).